Lung inflammatory pattern and antibiotic treatment in pneumonia

Respiratory Research

Table 1 General characteristics, comorbidity, initial pneumonia severity and antimicrobial therapy of the study population

	*NCAP*	*CAP control*	*Non-infection control*	p value*
Subjects, n	52	15	19
Age, years	61 ± 2	66 ± 4	61 ± 2	NS
Male/Female	31/21	12/3	16/3	NS
Current smoker, n	16	2	9	NS
Comorbidity, n
- Cerebrovascular disease	11(21)	3(20)	2(10)	NS
- Heart disease	12(23)	3(20)	2(10)	NS
- COPD	7(14)	7(46)	7(37)	0.01
PSI score	98 ± 4	102 ± 7	N/A	NS
CRP (mg/dl)			N/A
- At admission	232 ± 25	190 ± 30		NS
- At enrolment	165 ± 18	68 ± 21		0.05
Inhaled corticosteroids	2(29)	1(14)	0(15)	NS
Systemic corticosteroids	2(29)	3(43)	0	NS
Antimicrobial therapy^β, n			N/A
- Fluoroquinolone	6(12)	5(33)
- β-lactam plus macrolide	23(44)	9(60)
- β-lactam plus fluoroquinolone	8(15)	0
- Others regimens**	15(28)	1(7)

Data are expressed as mean ± SEM or n(%). *Mann–Whitney U test and chi-square test for continuous and categorical variables, respectively.
NCAP: non-responders pneumonia; CAP: community-acquired pneumonia; COPD: chronic obstructive pulmonary disease; PSI score: Pneumonia Severity Index score; CRP: C-reactive protein; NS: non-significant. N/A: not applicable.
^βAntimicrobial therapy at enrolment of the study.
Other regimens ^**vancomycin, imipemen-cilastatin, piperacillin-tazobactam, amikacin, clindamycin, ceftazidime, ertapenem and linezolid.

ISSN: 1465-993X